These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35197915)

  • 1. Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple Sclerosis.
    Bruno A; Dolcetti E; Centonze D
    Front Neurol; 2021; 12():802918. PubMed ID: 35197915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Broad Concept of "Spasticity-Plus Syndrome" in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms.
    Fernández Ó; Costa-Frossard L; Martínez-Ginés M; Montero P; Prieto JM; Ramió L
    Front Neurol; 2020; 11():152. PubMed ID: 32256440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain.
    Goicochea Briceño H; Higueras Y; Ruiz Pérez I; García Domínguez JM; Cuello JP; Meldaña Rivera A; Martínez Ginés ML
    Front Neurol; 2024; 15():1360032. PubMed ID: 38469589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis.
    Fernández Fernández Ó; Costa-Frossard L; Martínez Ginés ML; Montero Escribano P; Prieto González JM; Ramió-Torrentà L; Aladro Y; Alonso Torres A; Álvarez Rodríguez E; Labiano-Fontcuberta A; Landete Pascual L; Miralles Martínez A; Moral Torres E; Oliva-Nacarino P
    Front Neurol; 2024; 15():1371644. PubMed ID: 38708001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat
    Fernandez O; Costa-Frossard L; Martínez-Ginés ML; Montero P; Prieto-González JM; Ramió-Torrentà L
    Front Neurol; 2021; 12():722801. PubMed ID: 34646229
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.
    Pryce G; Baker D
    Br J Pharmacol; 2007 Feb; 150(4):519-25. PubMed ID: 17220914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
    de Lago E; Moreno-Martet M; Cabranes A; Ramos JA; Fernández-Ruiz J
    Neuropharmacology; 2012 Jun; 62(7):2299-308. PubMed ID: 22342378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic therapy of multiple sclerosis.
    Markowitz C
    Continuum (Minneap Minn); 2010 Oct; 16(5 Multiple Sclerosis):90-104. PubMed ID: 22810600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing the symptoms of multiple sclerosis: a multimodal approach.
    Crayton HJ; Rossman HS
    Clin Ther; 2006 Apr; 28(4):445-60. PubMed ID: 16750459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do cannabinoids reduce multiple sclerosis-related spasticity?
    Thaera GM; Wellik KE; Carter JL; Demaerschalk BM; Wingerchuk DM
    Neurologist; 2009 Nov; 15(6):369-71. PubMed ID: 19901724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
    Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
    Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Syed YY; McKeage K; Scott LJ
    Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoids control spasticity and tremor in a multiple sclerosis model.
    Baker D; Pryce G; Croxford JL; Brown P; Pertwee RG; Huffman JW; Layward L
    Nature; 2000 Mar; 404(6773):84-7. PubMed ID: 10716447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current pharmacologic treatment of multiple sclerosis symptoms.
    Andersson PB; Goodkin DE
    West J Med; 1996 Nov; 165(5):313-7. PubMed ID: 8993211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endocannabinoid system and multiple sclerosis.
    Baker D; Pryce G
    Curr Pharm Des; 2008; 14(23):2326-36. PubMed ID: 18781983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cannabinoid CB1 and CB2 receptors expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival.
    Theocharis S; Giaginis C; Alexandrou P; Rodriguez J; Tasoulas J; Danas E; Patsouris E; Klijanienko J
    Tumour Biol; 2016 Mar; 37(3):3647-56. PubMed ID: 26459312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Big conductance calcium-activated potassium channel openers control spasticity without sedation.
    Baker D; Pryce G; Visintin C; Sisay S; Bondarenko AI; Vanessa Ho WS; Jackson SJ; Williams TE; Al-Izki S; Sevastou I; Okuyama M; Graier WF; Stevenson LA; Tanner C; Ross R; Pertwee RG; Henstridge CM; Irving AJ; Schulman J; Powell K; Baker MD; Giovannoni G; Selwood DL
    Br J Pharmacol; 2017 Aug; 174(16):2662-2681. PubMed ID: 28677901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.